BiotechTube
SciTech Development

SciTech Development

Grosse Pointe Farms, United States· Est.
scitechdevelopment.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

SciTech Development has developed a proprietary nanoparticle Drug Delivery Platform (SDP) designed to enhance the bioavailability of water-insoluble therapeutics, particularly in oncology. Its lead program, ST-001 nanoFenretinide, reformulates the investigational drug fenretinide for intravenous delivery, aiming to unlock its full clinical potential in cancers where low bioavailability has historically been a barrier. The company is clinical-stage, supported by NCI funding, and is seeking partnerships and funding to advance trials, with an estimated 2-3 year path to market for its lead asset. The SDP platform also holds potential for delivering other insoluble drugs beyond oncology.

Oncology

Technology Platform

Proprietary nanoparticle Drug Delivery Platform (SDP) using a biomimetic phospholipid matrix to solubilize and deliver water-insoluble therapeutics intravenously, aiming to maximize bioavailability and improve safety profiles.

Opportunities

Validating the SDP with ST-001 could unlock a pipeline of reformulated insoluble drugs, both in oncology and other therapeutic areas.
The NCI backing provides credibility and non-dilutive funding to advance the lead program.
Fenretinide's established safety profile and multiple mechanisms of action may support a broad label and combination therapy potential.

Risk Factors

High clinical risk that ST-001 fails to show improved efficacy or reveals new safety issues in trials.
Heavy reliance on securing additional funding or a strategic partnership to advance development.
Competition from other drug delivery technologies and novel oncology therapeutics targeting similar indications.

Competitive Landscape

SciTech competes in the crowded drug delivery technology space, facing other companies developing lipid nanoparticles, liposomes, and other solubilization platforms. For fenretinide specifically, competition may be limited but it faces indirect competition from all other therapies in its target cancer indications. The platform's differentiation hinges on demonstrating superior safety and bioavailability gains.

More companies in Drug Delivery & Formulation →More companies in United States →